Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients. The company recently reported its financial results for the fiscal year ended December 31, 2025.
For the full fiscal year 2025, the company reported total revenue of $44.6 million in net product sales. The basic and diluted net loss per common share (EPS) for the twelve months ended December 31, 2025, was $(0.35).
Fennec concluded 2025 with $36.8 million in cash and cash equivalents. The company bolstered its financial position by completing an oversubscribed $42 million equity offering.